|
|
Blood, 15 November 2006, Vol. 108, No. 10, pp. 3289-3294.
Prepublished online as a Blood First Edition Paper on July 27, 2006; DOI 10.1182/blood-2006-05-022962.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal,
Jean-Luc Harousseau,
Serge Leyvraz,
Chantal Doyen,
Cyrille Hulin,
Lofti Benboubker,
Ibrahim Yakoub Agha,
Jean-Henri Bourhis,
Laurent Garderet,
Brigitte Pegourie,
Charles Dumontet,
Marc Renaud,
Laurent Voillat,
Christian Berthou,
Gerald Marit,
Mathieu Monconduit,
Denis Caillot,
Bernard Grobois,
Herve Avet-Loiseau,
Philippe Moreau,
Thierry Facon, for the Inter-Groupe Francophone du Myélome (IFM)
From the Department of Hematology, Hôpital Purpan, Toulouse, France; the Department of Biostatistics, Hôpital Purpan, Toulouse, France; the Hôtel Dieu, Nantes, France; the Centre Hospitalier Universitaire, Lausanne, Switzerland; the Cliniques Universitaires de Mont-Godinne, Yvoir, Belgium; the Centre Hospitalier Brabois, Nancy, France; the Hôpital Bretonneau, Tours, France; the Hôpital C. Huriez, Lille, France; the Institut Gustave Roussy, Villejuif, France; the Hôpital St-Antoine, Paris, France; the Hôpital Albert Michallon, Grenoble, France; the Hôpital Edouard Herriot, Lyon, France; the Centre Hospitalier la Mileterie, Poitiers, France; the Hôpital Jean Minjoz, Besançon, France; the Hôpital A. Morvan, Brest, France; the Hôpital Haut-Lévèque, Bordeaux Pessac, France; the Centre Henri Becquerel, Rouen, France; the Centre Hospitalier Le Bocage, Dijon, France; and the Hôpital Sud, Rennes, France.
Newer chemotherapeutic protocols as well as high-dose chemotherapy have increased the response rate in myeloma. However, these treatments are not curative. Effective maintenance strategies are now required to prolong the duration of response. We conducted a randomized trial of maintenance treatment with thalidomide and pamidronate. Two months after high-dose therapy, 597 patients younger than age 65 years were randomly assigned to receive no maintenance (arm A), pamidronate (arm B), or pamidronate plus thalidomide (arm C). A complete or very good partial response was achieved by 55% of patients in arm A, 57% in arm B, and 67% in arm C (P = .03). The 3-year postrandomization probability of event-free survival was 36% in arm A, 37% in arm B, and 52% in arm C (P < .009). The 4-year postdiagnosis probability of survival was 77% in arm A, 74% in arm B, and 87% in arm C (P < .04). The proportion of patients who had skeletal events was 24% in arm A, 21% in arm B, and 18% in arm C (P = .4). Thalidomide is an effective maintenance therapy in patients with multiple myeloma. Maintenance treatment with pamidronate does not decrease the incidence of bone events.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Exciting new agents in multiple myeloma
- Giampaolo Merlini
Blood 2006 108: 3235-3236.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S. Giralt, D. H. Vesole, G. Somlo, A. Krishnan, E. Stadtmauer, P. Mccarthy, M. C. Pasquini;, and on behalf of the Blood and Marrow Transplant Clini
Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
J Natl Cancer Inst,
July 1, 2009;
101(13):
964 - 964.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Tricot, S. E. Kern, and B. Barlogie
Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
J Natl Cancer Inst,
July 1, 2009;
101(13):
964 - 966.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-L. Harousseau and P. Moreau
Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
N. Engl. J. Med.,
June 18, 2009;
360(25):
2645 - 2654.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al.
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
Ann. Onc.,
May 22, 2009;
(2009)
mdn796v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-L. Harousseau, M. Dreyling, and On behalf of the ESMO Guidelines Working Group
Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc.,
May 1, 2009;
20(suppl_4):
iv97 - iv99.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Spencer, H. M. Prince, A. W. Roberts, I. W. Prosser, K. F. Bradstock, L. Coyle, D. S. Gill, N. Horvath, J. Reynolds, and N. Kennedy
Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
J. Clin. Oncol.,
April 10, 2009;
27(11):
1788 - 1793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Stewart
Reduced-intensity allogeneic transplantation for myeloma: reality bites
Blood,
April 2, 2009;
113(14):
3135 - 3136.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
J. Clin. Oncol.,
June 1, 2008;
26(16):
2761 - 2766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Palumbo, F. Gay, S. Bringhen, A. Falcone, N. Pescosta, V. Callea, T. Caravita, F. Morabito, V. Magarotto, M. Ruggeri, et al.
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
Ann. Onc.,
June 1, 2008;
19(6):
1160 - 1165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Lazarus, G. L. Phillips, R. H. Herzig, D. D. Hurd, S. N. Wolff, and G. P. Herzig
High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later
J. Clin. Oncol.,
May 10, 2008;
26(14):
2240 - 2243.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Palumbo, T. Facon, P. Sonneveld, J. Blade, M. Offidani, F. Gay, P. Moreau, A. Waage, A. Spencer, H. Ludwig, et al.
Thalidomide for treatment of multiple myeloma: 10 years later
Blood,
April 15, 2008;
111(8):
3968 - 3977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mehta
One or two autografts for myeloma?
Blood,
April 1, 2008;
111(7):
3899 - 3900.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Abdelkefi, S. Ladeb, L. Torjman, T. B. Othman, A. Lakhal, N. B. Romdhane, H. E. Omri, M. Elloumi, H. Belaaj, R. Jeddi, et al.
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial
Blood,
February 15, 2008;
111(4):
1805 - 1810.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Bensinger
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
J. Clin. Oncol.,
January 20, 2008;
26(3):
480 - 492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Lokhorst, I. Schmidt-Wolf, P. Sonneveld, B. van der Holt, H. Martin, R. Barge, U. Bertsch, J. Schlenzka, G. M.J. Bos, S. Croockewit, et al.
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
Haematologica,
January 1, 2008;
93(1):
124 - 127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Katzel, P. Hari, and D. H. Vesole
Multiple Myeloma: Charging Toward a Bright Future
CA Cancer J Clin,
September 1, 2007;
57(5):
301 - 318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
ASCO 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma: Guideline Summary
J. Oncol. Pract,
July 1, 2007;
3(4):
236 - 236.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cavo, P. Tosi, E. Zamagni, C. Cellini, P. Tacchetti, F. Patriarca, F. Di Raimondo, E. Volpe, S. Ronconi, D. Cangini, et al.
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
J. Clin. Oncol.,
June 10, 2007;
25(17):
2434 - 2441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Kyle, G. C. Yee, M. R. Somerfield, P. J. Flynn, S. Halabi, S. Jagannath, R. Z. Orlowski, D. G. Roodman, P. Twilde, and K. Anderson
American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma
J. Clin. Oncol.,
June 10, 2007;
25(17):
2464 - 2472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Carlo-Stella, A. Guidetti, M. Di Nicola, C. Lavazza, L. Cleris, D. Sia, P. Longoni, M. Milanesi, M. Magni, Z. Nagy, et al.
IFN-{gamma} Enhances the Antimyeloma Activity of the Fully Human Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3
Cancer Res.,
April 1, 2007;
67(7):
3269 - 3275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. G. M. Durie and IMWG
Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement
Mayo Clin. Proc.,
April 1, 2007;
82(4):
516 - 517.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Q. Lacy, S. V. Rajkumar, and Mayo Clinic Myeloma Group
Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement-Reply-I
Mayo Clin. Proc.,
April 1, 2007;
82(4):
517 - 518.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca and A. K. Stewart
Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach
Mol. Cancer Ther.,
March 1, 2007;
6(3):
802 - 810.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al.
Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
Mayo Clin. Proc.,
March 1, 2007;
82(3):
323 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Attal, P. Moreau, H. Avet-Loiseau, and J.-L. Harousseau
Stem Cell Transplantation in Multiple Myeloma
Hematology,
January 1, 2007;
2007(1):
311 - 316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
